Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe Fat-Immune link in rare and common metabolic diseases

NCT ID NCT01784289

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 126 people with different fat distribution patterns—including those with lipodystrophy (abnormal fat loss or distribution), obesity, and normal weight—to understand how fat tissue relates to insulin resistance and immune signals. Researchers measured blood levels of interleukin-7 and other immune markers, along with fat mass using scans. The goal was to gather knowledge, not to test a treatment, so no direct benefit for participants was expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

126 people

The number who actually took part.

Start date

Jun 2010

Finished

Jun 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with lipodystrophy : Endocrinology Departments of Lille , Amiens, Caen, Rouen and Reims University hospitals. Obese (diabetics and non diabetics) and normal weight patients : Endocrinology - Metabolism, Endocrine Surgery and Nutrition Departments, Lille University Hospital

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and Female * More than 18 years old * with lipodystrophic syndrome (familial, partial, genetically determined), diabetics or not, obese or not * Patients with lipodystrophy non related to a lamine A/C gene mutation, diabetics or not, obese or not * Obese without diabetes (BMI\> 30) * Obese (BMI\>30) and diabetes according to ADA criteria * Normal weight patients (18\< BMI\< 25) * Agreement for the establishment of a serum bank and a plasma bank Exclusion Criteria: * Unable to receive enlightened information * Refusal to sign the consent * Corticosteroids (including inhaled), other immunosuppressing treatments (systemic disease for example) or immunomodulators (eg interferon); * Creatinin \> 15 mg / L * Sepsis * Progressing cancers or autoimmune diseases; * Treatment, disease or other condition that may affect the rate of IL-7 (as some contraceptives with estrogens) * Bleeding disorders (due to disease or treatment) * Active alcohol Intoxication * Psychiatric pathology (after psychiatric consultation) * Active infection including hepatitis C or HIV; * Age under 18 years * Participation in another study excluded the possibility of participating in another protocol * BMI \> 60 * Secondary diabetes * No social security * Pregnant or lactating women, patients under guardianship, persons deprived of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lipodystrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lipodystrophy Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lipodystrophy Obesity Type 2 diabetes

Contacts and locations

Locations

  • Amiens University Hospital

    Amiens, 80054, France

  • Caen University Hospital

    Caen, 14032, France

  • Lille University Hospital

    Lille, 59037, France

  • Reims University Hospital

    Reims, 51092, France

  • Rouen University Hospital

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.